Does the Non-surgical Application of Enamel Matrix Derivative Reduce the Need of Periodontal Surgical Intervention in Subjects With Severe (Stage III) Periodontitis?
Periodontal Diseases
About this trial
This is an interventional treatment trial for Periodontal Diseases
Eligibility Criteria
Inclusion Criteria
- Accept the form of the study and signs a declaration of informed consent; understand and are willing, able and likely to comply with all study procedures and restrictions.
- Systemically healthy (according to exclusion criteria 4) participants of either genders who are attending a periodontal centre for periodontal care.
- Aged 18 or over.
- Presenting at least 20 teeth (excluded wisdom teeth).
- Being affected by generalized Periodontitis (stage III) irrespectively of the grade (Tonetti et al., 2018) i.e. presenting at least 5 mm of clinical atattachment loss at the interdental areas, radiographic bone resorption of more than 30% of the root length extending to at least the middle portion of the root, less than 5 teeth lost for periodontal reason, presenting characteristics for complexity (intrabony defects, furcation defects, moderate ridge defects)
- Bleeding on probing on at least 30% of the sites and a minimum of 4 teeth with at least one site with PPD ≥6mm
Exclusion Criteria:
- Persons incapable of responding to the questions.
- An employee of the sponsor, employee of the general dental practice, and/or a family relative of the employees mentioned above.
- Women known to be pregnant or lactating (a specific declaration form will be signed by the patient, stating the non-pregnant or lactating status).
- Persons suffering of pathologies known to affect the outcome of periodontal therapy (i.e. diabetes, osteoporosis, immunosuppression).
- Persons undergoing therapy which will may complicate adherence to protocol or showing an impact on periodontal outcome (i.e. chemotherapy and immunosuppressive treatments).
- Persons who require antibiotic coverage (following infectious endocarditis, using prosthetic cardiac valves, other pathologies).
- Persons undergoing pharmacological treatment associated with gingival hypertropia development (phenytoin, phenobarbital, lamotrigine, vigabatrin, ethosuximide, topiramate, primidone, nifedipine, amlodipine, verapamil, cyclosporine).
Persons with implant-supported restorations affected by peri-implantitis (as defined by the 2017 Classification, i.e. presence of bleeding and/or suppuration on gentle probing, probing depths of ≥6 mm, bone levels ≥3 mm apical of the most coronal portion of the intraosseous part of the implant).
- Smokers declaring to smoke more than 20 cigarettes per day.
- Persons with Body Mass Index above 29(obese subjects).
- Anyone who in the investigators' opinion is not suitable to take part in the study.
- Allergy/idiosyncrasy to anaesthesia or components of the device object of the study.
- Previous periodontal subgingival instrumentation within the previous 12 months.
- Antibiotics intake in the previous 3 months.
Sites / Locations
- University Hospital of PisaRecruiting
- Azienda Ospedaliero Universitaria PisanaRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Enamel Matrix Derivative application
Saline application
At the completion of the subgingival instrumentation, in all sites with PPD>6 mm, a solution of 24% EDTA, will be first applied with a sterile syringe with a thin blunt tip (25GX1/4"). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
At the completion of the subgingival instrumentation, in all sites with PPD>5 mm, a solution of 24% EDTA , will be first applied with a sterile syringe with a thin blunt tip (25GX1/4"). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.